{"nctId":"NCT00637377","briefTitle":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","startDateStruct":{"date":"2008-04"},"conditions":["Macular Degeneration"],"count":1240,"armGroups":[{"label":"Ranibizumab 0.5mg Q4","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab"]},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4","type":"EXPERIMENTAL","interventionNames":["Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)"]},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4","type":"EXPERIMENTAL","interventionNames":["Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)"]},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8","type":"EXPERIMENTAL","interventionNames":["Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)"]}],"interventions":[{"name":"Ranibizumab","otherNames":[]},{"name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent.\n* Men and women \\>/=50 years of age.\n* Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA) in the study eye.\n* ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters.\n* Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.\n* Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.\n* Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.\n* Any prior treatment with anti-VEGF agents in the study eye.\n* Total lesion size \\>12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.\n* Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).\n* Scar or fibrosis making up \\>50% of the total lesion in the study eye.\n* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.\n* History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.\n* Presence of other causes of CNV in the study eye.\n* Prior vitrectomy in the study eye.\n* History of retinal detachment or treatment or surgery for retinal detachment in the study eye.\n* Any history of macular hole of stage 2 and above in the study eye.\n* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)","description":"Maintenance of vision was defined as a loss of \\< 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.\n\nNominator = (Number of participants who maintained vision \\* 100); Denominator = Number of participants analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.42","spread":null},{"groupId":"OG001","value":"95.62","spread":null},{"groupId":"OG002","value":"96.27","spread":null},{"groupId":"OG003","value":"95.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF","description":"Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"13.5"},{"groupId":"OG001","value":"7.6","spread":"12.6"},{"groupId":"OG002","value":"9.7","spread":"14.1"},{"groupId":"OG003","value":"8.9","spread":"14.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF","description":"Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.\n\nNominator = (Number of participants who maintained vision \\* 100); Denominator = Number of participants analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.02","spread":null},{"groupId":"OG001","value":"29.45","spread":null},{"groupId":"OG002","value":"34.80","spread":null},{"groupId":"OG003","value":"31.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF","description":"The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"14.8"},{"groupId":"OG001","value":"4.5","spread":"15.0"},{"groupId":"OG002","value":"5.1","spread":"13.7"},{"groupId":"OG003","value":"4.9","spread":"14.7"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF","description":"CNV area values measured in square millimeters; lower values represent better outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.16","spread":"5.90"},{"groupId":"OG001","value":"-5.95","spread":"6.12"},{"groupId":"OG002","value":"-4.24","spread":"6.13"},{"groupId":"OG003","value":"-5.16","spread":"5.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":291},"commonTop":["Retinal haemorrhage","Visual acuity reduced","Macular degeneration","Hypertension","Conjunctival haemorrhage"]}}}